Join to learn about edasalonexent, a novel oral NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy, regardless of mutation type.
This webinar will include:
- An update on the currently enrolling global Phase 3 PolarisDMD trial
- An introduction to the open-label extension GalaxyDMD trial
- Results from the Phase 2 MoveDMD trial